News ArticleZydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Company reports total income of ₹66,425 million and earnings per share of ₹10.53 for H1 FY 2027 following board approval on November 4
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, reporting a net profit of ₹10,541 million for H1 FY 2027. The company recorded total revenue of ₹66,425 million for the half year, supported by sales of products amounting to ₹60,858 million. These results were reviewed and approved by the Audit Committee and Board of Directors on November 4, 2026.
Zydus Lifesciences Limited
Financial Results
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
The total income for the half year reached ₹66,425 million, including revenue from operations of ₹63,542 million, driven primarily by sales of products totaling ₹60,858 million.
The company's expenses amounted to ₹52,228 million for the half year, including cost of materials, employee benefits, and other operational costs.
Profit before exceptional items and tax stood at ₹14,197 million for H1 FY 2027, while an exceptional expense of ₹19 million was recognized due to asset damage from torrential rains and related provisions.
The company’s earnings per share (EPS) for the half year were ₹10.53, based on a paid-up equity share capital of ₹998 million with a face value of Re. 1 each.
The financial results were reviewed by Deloitte Haskins & Sells LLP and approved by Zydus Lifesciences’ Board of Directors on November 4, 2026, while trading restrictions for insiders remain in place till November 6, 2026.
Highlights
- Net profit of ₹10,541 million for half year ended September 30, 2026.
- Total income of ₹66,425 million in H1 FY 2027, driven by ₹60,858 million in product sales.
- Earnings per share of ₹10.53 for the half year.
- Exceptional item of ₹19 million related to asset damage from rains.
- Financial results reviewed by Deloitte and approved November 4, 2026.
Key Data Snapshot
What happened
- Zydus Lifesciences approved its standalone unaudited financial results for Q2 and H1 FY 2027 on November 4, 2026.
- The results include a half year net profit of ₹10,541 million.
- Total income for the half year stood at ₹66,425 million with significant contribution from product sales.
Key details
- Earnings per share for the half year were ₹10.53 based on paid-up equity capital of ₹998 million.
- Exceptional items of ₹19 million reflected provisions for asset damage due to torrential rains and related insurance claims.
- Expenses for the half year totaled ₹52,228 million, including material costs, employee benefits, and finance costs.
Regulatory and governance context
- Financial results were reviewed by the company's independent auditors Deloitte Haskins & Sells LLP.
- The review was conducted in compliance with Indian Accounting Standard 34 and SEBI regulations.
- The trading window for directors and designated persons remains closed until November 6, 2026, reopening on November 9, 2026.
Highlights
- Net profit of ₹10,541 million for half year ended September 30, 2026.
- Total income of ₹66,425 million in H1 FY 2027, driven by ₹60,858 million in product sales.
- Earnings per share of ₹10.53 for the half year.
- Exceptional item of ₹19 million related to asset damage from rains.
- Financial results reviewed by Deloitte and approved November 4, 2026.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 (Interim Financial Reporting)
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
Clean Max Enviro Energy Solutions Plans INR 3000 Crore Debenture Issue and Sets Up IFSC Subsidiary in GIFT City
Clean Max Enviro Energy Solutions Limited announced a plan to raise up to INR 30,00,00,00,000 (INR 3000 crore) through issuance of listed, rated, redeemable non-convertible debentures via private placement. The debentures are to be listed on the Wholesale Debt Market segment of BSE Limited and/or NSE Limited. The company also approved incorporation of a wholly owned subsidiary in the International Financial Services Centre (IFSC) in GIFT City, Gujarat. Additionally, the company released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30
Read Full Story
